3.

Univariate and multivariate analyses for risk factors of CRT

Variables	Univariate analysis			Multivariate analysis*
	HR (95% CI)	P		HR (95% CI)	P
CRT, chemoport-related thrombosis; BMI, body mass index; AC, adjuvant chemotherapy; PC, palliative chemotherapy; HR, hazard ratio; 95% CI, 95% confidence interval; *, using significant risk factors (P<0.1) in univariate analysis.
Sex (male/female)	1.19 (0.70–2.03)	0.522
Age (>65 years)	1.01 (0.62–1.89)	0.774
BMI (>30 kg/m2)	0.92 (0.13–6.66)	0.937
Prior thromboembolism	3.46 (0.84–14.17)	0.085		3.01 (0.75–12.84)	0.119
Diabetes	0.57 (0.23–1.41)	0.221
Hypertension	1.06 (0.62–1.80)	0.840
Hyperlipidemia	1.37 (0.33–5.60)	0.663
Cardiovascular disease	1.08 (0.34–3.45)	0.897
Abnormal liver function	0.37 (0.05–2.70)	0.329
Prior primary site resection	1.03 (0.51–2.09)	0.935
Prior metastasectomy	1.37 (0.70–2.70)	0.363
Prior palliative surgery	1.80 (0.65–4.97)	0.254
Prior chemotherapy	1.47 (0.86–2.51)	0.158
Prior anticoagulation	2.71 (0.98–7.49)	0.054		2.71 (0.98–7.48)	0.054
Metastasis (Y/N)	1.63 (0.95–2.79)	0.077		0.97 (0.45–2.07)	0.928
With or without bevacizumab
With	2.06 (1.24–3.43)	0.006		2.06 (1.24–3.43)	0.006
Without	1			1
Treatment settings and bevacizumab administration
AC	1
PC without bevacizumab	1.01 (0.47–2.15)	0.986
PC with bevacizumab	2.06 (1.17–3.65)	0.013
PC without bevacizumab	1
PC with bevacizumab	2.05 (1.00–4.21)	0.040